{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1, 2009): Complete Response (CR): Disappearance all lesions including normalization of elevated tumor marker level; Pathological lymph nodes reduction in short axis to \\<10 mm. Partial Response (PR): \\>30% decrease sum longest diameters (LD) of lesions reference baseline sum LD. Progressive Disease (PD): \\>20% increase (absolute increase \\>5 mm) in sum LD measured lesions references smallest sum LD, and appearance new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD. After a tumor demonstrates a tumor response (partial or complete), confirmation of the response obtained by a second evaluation to be performed 2 cycles later (+/- 1week) \\[second tumor assessment not \\<4 weeks from response observed\\]. Assessed via computed tomography (CT) of the chest, abdomen, and pelvis.","groups":[{"description":"Abraxane 220 mg/m\\^2 intravenously on Day 1 of 21 day cycle.","id":"OG000","title":"CIMP-high Colorectal Cancer"},{"description":"Abraxane 220 mg/m\\^2 intravenously on Day 1 of 21 day cycle.","id":"OG001","title":"Small Bowel Adenocarcinoma (SBA)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"In the CIMP-CRC arm 15 participants were considered efficacy evaluable \\[Of 21 treated, 6 participants were withdrawn due to toxicity (2) and due to clinical progression (4)\\], and three were not evaluable in SBA arm.","reportingStatus":"POSTED","timeFrame":"Assessed at 21 day cycle; Restaging done every 3 cycles","title":"Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA)","type":"PRIMARY","unitOfMeasure":"Participants"}